Lyell Immunopharma
LYEL
LYEL
127 hedge funds and large institutions have $297M invested in Lyell Immunopharma in 2024 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 36 increasing their positions, 44 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
0% less ownership
Funds ownership: 2.62% → 2.61% (-0%)
7% less call options, than puts
Call options by funds: $14K | Put options by funds: $15K
18% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 44
Holders
127
Holding in Top 10
4
Calls
$14K
Puts
$15K
Top Buyers
| 1 | +$7.48M | |
| 2 | +$2.54M | |
| 3 | +$1.1M | |
| 4 |
D.E. Shaw & Co
New York
|
+$833K |
| 5 |
Renaissance Technologies
New York
|
+$782K |
Top Sellers
| 1 | -$6M | |
| 2 | -$3.21M | |
| 3 | -$1.23M | |
| 4 |
HF
HRT Financial
New York
|
-$963K |
| 5 |
BlackRock
New York
|
-$913K |